Navigation Links
USHIFU, LLC Completes Acquisition of Focus Surgery, Inc.
Date:7/2/2008

prostate cancer, including Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical trials in the United States to gather data important for analysis of the technology by the FDA. The first is a pivotal trial for the treatment of primary organ confined prostate cancer that will enroll 466 participants at 24 different centers. A second pivotal trial will begin for the treatment of recurrent prostate cancer in men who have failed external beam radiation therapy. This single arm study will enroll 202 participants at 10 different sites.

About the Sonablate(R) 500

The Sonablate(R) 500 is a non-invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by FSI and is manufactured by Misonix, Inc. (Nasdaq: MSON) who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate(R) 500 in Southeast Asia and the Middle East.

The Sonablate(R) 500 is not approved for use in the U.S. The Sonablate(R) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate(R) 500 for the treatment of prostate cancer.


'/>"/>
SOURCE USHIFU, LLC
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Southern Home Medical Equipment Completes 1-for-1,000 Reverse Split and Begins Trading Under New Symbol SHOM
2. KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
3. Beeston completes drilling on Bluff Lake property, 100 Mile House
4. PreMD Successfully Completes Project for Health & Beauty Company
5. Sinexus Welcomes New CEO and Completes Series B
6. ACTS Retirement-Life Communities Completes Carlton Cove Acquisition
7. Health Fitness Completes Share Repurchase Plan
8. Lockheed Martin Completes Acquisition of Eagle Group International, LLC
9. The Quantum Group Completes Corporate Expansion Plan; Employee and Corporate Office Growth Leads the Way for Enhanced Innovation and Growth Through 2009
10. Mindray Medical Completes Acquisition of Datascopes Patient Monitoring Business
11. Takeda Completes Acquisition of Millennium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)...-FirstCall/ -- Eli Lilly and Company,(NYSE: LLY...rth quarter and,full year of 2008 on Thursday, Ja...ence call on that day with the investment communit...cial performance. , The conference call wil...tors, media and the general public can access a li...
(Date:1/7/2009)...ung disease , , WEDNESDAY, Jan. 7 (Healt... to deer mice might mean focusing on the older and...ad the disease, researchers from the University of...irus, the hantavirus -- meaning a virus spread by ...ng disease in people that has proven fatal about 3...
(Date:1/7/2009)...inal muscular atrophy (SMA), a genetic disorder th...ing genetic cause of infant death, but University ...apeutic target that improves deteriorating skeleta...anced muscle strength, improved gross motor skills..."This therapy does not directly target the disease...
(Date:1/7/2009)...swire/ -- The surgical lights are on, the,operati...e West Coast,s most,advanced pediatric surgery ce...tanford . , (Photo: http://www.newscom.co...n new operating rooms, which opened in December, p...chnologies, allowing surgeons to operate,with unp...
Breaking Medicine News(10 mins):Health News:Old, Fat Mice Blamed for Virus Transmission 2Health News:Researchers discover target that could ease spinal muscular atrophy symptoms 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 2Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 3Health News:Packard Children's Opens West Coast's Most Advanced Pediatric Surgery Center 4
...rism drives you to buy a gas mask at the nearest a...urself for what experts say about them -- most of ...osure is; you'd have to wear the mask at all times... to your health would probably be higher than the ...
...e which may harm the brain areas involved in Parki...or Parkinson's disease - the doctor has to rely on... known that cells producing a chemical called dopa...a of the brain called the substantia nigra slowly ...
...Nobel Prize in Chemistry: William S. Knowles, prev...SA; Ryoji Noyori, Nagoya University, Chikusa, Nago...arch Institute, La Jolla, California, USA. They we...alytic asymmetric synthesis. The Laureates have de...
...develop Alzheimer's Disease as people who have nev...the largest ever of its kind and the first major r...eimer's - followed 5,369 men and women aged 57 and...eimer's, the most common form of dementia, before ...
Other Medicine News:
(Date:1/7/2009)..., BEIJING, Jan. 7 Tiantan Puhua H...hua.com ), the worldwide leader in using stem cell...ounced today six new globally experienced addition...ntly expand the hospital,s treatment capabilities ...ents. The six senior doctors include the distingui...
(Date:1/6/2009)..., NEW YORK, Jan. 6 The...t $2.7 million to four industry research teams for... for Parkinson,s disease. , , The funding was a...pment Initiative. This program, first launched in...rts on Parkinson,s research. TDI is part of MJFF...
(Date:1/5/2009)..., SAN DIEGO, Jan. 5 Cylene Pharma...Phase I clinical trial of its oral CK2 protein kin...solid tumors, Castleman,s disease, or multiple mye...ating trial are determination of safety, tolerance...propriate dose for Phase II trials. In addition, m...
(Date:12/29/2008)..., BETHESDA, Md., Dec. 29 /PRNewswire-USNewswire/ ...Human Research Protection was announced today by D...the Health Improvement Institute. , , The winn...xas M.D. Anderson Cancer Center -- for its best..." This program provides for 1) enhanced human sub...
Breaking Medicine Technology:Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 2Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2 32008 Human Research Protection Award Recipients Announced 2New Michael J Fox Foundation Initiative Will Drive Development of Web Based Tools to Increase Patient Participation in Parkinsons Clinical Trials 1562 1New Michael J Fox Foundation Initiative Will Drive Development of Web Based Tools to Increase Patient Participation in Parkinsons Clinical Trials 1562 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 1Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 2Columbia University Medical Center NYPH receive 2428 million donation toward curing diabetes 14747 3Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 1Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 2Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 3Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 4Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals 14745 5Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 1Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 2Spartan Stores Becomes Largest U S Supermarket Chain to Receive NSF Shop Fresh 28TM 29 Certification 14743 3
...un 1, 2007 - A therapeutic,vaccine developed by th...mises new hope for cancer patients. The results of...resented to an,international audience at the Annua...Oncology (ASCO) in Chicago, USA. ASCO is the,most ...ialists,world-wide., The active substance VPM4001,...
... 1, 2007 - OXiGENE, Inc.,(NASDAQ: OXGN, XSSE: OXGN...loping novel therapeutics to treat cancer and eye,...bstracts in the,2007 Annual Meeting program distri...American Society of Clinical Oncology (ASCO),in Ch...st time full data from a,randomized Phase II trial...
Other Medicine Technology:Vakzine Projekt Management Reports Positive Clinical Trial Results,With Their Therapeutic Prostate Cancer Vaccine VPM4001 2OXiGENE Abstracts Published in ASCO Program 2OXiGENE Abstracts Published in ASCO Program 3OXiGENE Abstracts Published in ASCO Program 4
Inquire
CO2 gas object holder and knife freezer for the 8000 Series Sliding Microtome
Steel Knife with box for the Series 8000 Sliding Microtome. C-Profile, 240 x 33 x13m, 22 Degree angle, tapped to accept holder for Shandon knife sharpener.
Allows for custom orientation of specimen
Medicine Products: